Menu
US
img-spleen-targeted-neoantigen-dna-vaccine-personalized-immunotherapy-hepatocellular-carcinoma-1920x640
Literature - Publication Review

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Researchers investigated how a spleen-targeted DNA vaccine, delivered via RBC-hitchhiked nanoparticles, effectively induced robust neoantigen specific T cell responses in hepatocellular carcinoma (HCC). This approach not only inhibited tumor growth, but also showed potential for complete tumor regression when combined with anti-PD-1 therapy, offering a promising strategy for personalized immunotherapy in HCC.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

Download Resource

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Download Literature - Publication Review